Gary J Doherty
Overview
Explore the profile of Gary J Doherty including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
31
Citations
2440
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sun G, Arango-Argoty G, Doherty G, Bikiel D, Pavlovic D, Chen A, et al.
iScience
. 2024 Sep;
27(9):110634.
PMID: 39246446
System-level patient health signals, as captured by treatment-emergent adverse events (TEAEs), might contain correlates of immune checkpoint inhibitor (ICI) therapy response. Using all TEAEs and a novel machine learning modeling...
2.
Abbosh C, Hodgson D, Doherty G, Gale D, Black J, Horn L, et al.
Trends Cancer
. 2024 Jun;
10(7):643-654.
PMID: 38839544
Systemic treatment of resectable non-small cell lung cancer (NSCLC) is evolving with emerging neoadjuvant, perioperative, and adjuvant immunotherapy approaches. Circulating tumor DNA (ctDNA) detection at clinical diagnosis, during neoadjuvant therapy,...
3.
Heymach J, Harpole D, Mitsudomi T, Taube J, Galffy G, Hochmair M, et al.
N Engl J Med
. 2023 Oct;
389(18):1672-1684.
PMID: 37870974
Background: Neoadjuvant or adjuvant immunotherapy can improve outcomes in patients with resectable non-small-cell lung cancer (NSCLC). Perioperative regimens may combine benefits of both to improve long-term outcomes. Methods: We randomly...
4.
Haston S, Gonzalez-Gualda E, Morsli S, Ge J, Reen V, Calderwood A, et al.
Cancer Cell
. 2023 Jun;
41(7):1242-1260.e6.
PMID: 37267953
The accumulation of senescent cells in the tumor microenvironment can drive tumorigenesis in a paracrine manner through the senescence-associated secretory phenotype (SASP). Using a new p16-FDR mouse line, we show...
5.
Navani N, Butler R, Ibrahimo S, Verma A, Evans M, Doherty G, et al.
Lung Cancer
. 2022 Sep;
172:142-153.
PMID: 36099709
Targeted therapy against actionable variants has revolutionised the treatment landscape for non-small cell lung cancer (NSCLC). Approximately half of NSCLC adenocarcinomas have an actionable variant, making molecular testing a critical...
6.
Pugh T, Bell J, Bruce J, Doherty G, Galvin M, Green M, et al.
Cancer Discov
. 2022 Jul;
12(9):2044-2057.
PMID: 35819403
Significance: AACR Project GENIE has now accrued data from >110,000 tumors, placing it among the largest repository of publicly available, clinically annotated genomic data in the world. GENIE has emerged...
7.
Doherty G, Goksu M, de Paula B
Nat Cancer
. 2022 Feb;
1(6):568-572.
PMID: 35121973
No abstract available.
8.
Thompson N, Stewart G, Welsh S, Doherty G, Robinson M, Neville B, et al.
BMC Cancer
. 2022 Jan;
22(1):99.
PMID: 35073853
Background: The gut microbiome is implicated as a marker of response to immune checkpoint inhibitors (ICI) based on preclinical mouse models and preliminary observations in limited patient series. Furthermore, early...
9.
Kieran R, de Paula B, Hubank M, Barker A, Paterson A, Gilligan D, et al.
JCO Precis Oncol
. 2022 Jan;
5:1579-1583.
PMID: 34994644
No abstract available.
10.
Morsli S, Doherty G, Munoz-Espin D
Mech Ageing Dev
. 2022 Jan;
202:111618.
PMID: 34990647
Pharmacologically active compounds that manipulate cellular senescence (senotherapies) have recently shown great promise in multiple pre-clinical disease models, and some of them are now being tested in clinical trials. Despite...